P200 The clinical, utility and economic benefits of securing minimal important difference in asthma control test using a novel tool: the a.b.o.v.e. asthma (achieving-better-outcomes-and-value-for- everybody-in-asthma)

Manfrin, A and Tinelli, M (2017) P200 The clinical, utility and economic benefits of securing minimal important difference in asthma control test using a novel tool: the a.b.o.v.e. asthma (achieving-better-outcomes-and-value-for- everybody-in-asthma). British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017. Published in: Thorax. 72 (3) A191-A192. BMJ Publishing Group ISSN 0040-6376

[img] PDF - Published Version
Restricted to SRO admin only

Download (8MB)

Abstract

Introduction and objectives: Asthma accounts for an economic loss of €72 billion annually in the 28 countries of the European Union with a monetised value of DALYs cost of €38 billion. One of the key priorities in asthma management is achieving asthma control. It is crucial to understand whether providing a minimally clinical important difference (MID) of the asthma control test (ACT) score can bring better clinical, utility and economic outcomes.
Aim: To test whether the A.B.O.V.E. ASTHMA (Achieving-Better-Outcomes-and-Value-for-Everybody-in-Asthma) tool works in terms of securing the MID in ACT and, in doing so, we can provide positive outcomes for patients, payers, providers and policy makers.
Methods: Using the data obtained from the Italian Medicines Use Review (I-MUR) cluster randomised controlled trial (C-RCT; 2014-2015) involving 1,263 asthma patients and 283 pharmacists in Italy, we tested whether A.B.O.V.E. ASTHMA was able to (1) link a clinical outcome (ACT score) to economic and utility dimensions; (2) secure a MID improvement in ACT and the outcomes attached in terms of cost savings for the healthcare provider and gains in health utility (% of being in perfect health).
Results: Data from the C-RCT showed that after receiving the A.B.O.V.E. ASTHMA intervention, patients improved their asthma control, assessed by the ACT, shifting from not controlled (RED; ) towards partially controlled (YELLOW, ), and fully controlled (GREEN, ) groups. Asthma control improved in the vast majority of patients (median ACT score was 19 at baseline, 20 at 3-month and 21 at 6-month post intervention). The number of patients who were on MID target and reached the GREEN group ( ) at 3 and 6 months were 129 (15.8%) and 162 (19.9%) respectively. The overall annual cost savings per 1,000 patients attached to the shift towards the MID target was equal to: 346,012 euros (NHS) at 3 months and increased to 425,483 euros (NHS) at 6 months (see Table). Health utility gains were equal to 0.9 and 0.29 years in full health, respectively.
Conclusions: The A.B.O.V.E. ASTHMA tool can secure MID in ATC and, in doing so, better outcomes in terms of clinical, utility and economic results.

Item Type: Conference Proceedings
Keywords: Asthma, community pharmacy, pharmacist-led intervention, economic benefits, MID
Schools and Departments: School of Life Sciences > Biochemistry
Subjects: R Medicine > RS Pharmacy and materia medica
R Medicine > RS Pharmacy and materia medica > RS0153 Materia medica > RS0250 Commercial preparations. Patent medicines
Depositing User: Andrea Manfrin
Date Deposited: 27 Nov 2017 15:52
Last Modified: 27 Nov 2017 15:53
URI: http://sro.sussex.ac.uk/id/eprint/71612

View download statistics for this item

📧 Request an update